National Resilience, Inc.

National Resilience, Inc., commonly known as Resilience, is a technology-focused biomanufacturing company established in 2020. Its core mission is to broaden access to complex medicines and fortify biopharmaceutical supply chains against disruptions. The company aims to ensure that current and future medicines can be produced rapidly, safely, and at scale. Resilience recently relocated its corporate headquarters from San Diego, California, to Blue Ash, Ohio, in June 2026, consolidating its operations within the Cincinnati region.

Resilience operates as a Contract Development and Manufacturing Organization (CDMO), offering end-to-end biomanufacturing solutions for advanced therapies. Its services encompass biologics drug substance, cell-based therapies, aseptic drug product manufacturing for both small and large molecules, vaccines, cell and gene therapies, and nucleic acids. The company provides comprehensive development, scale-up, and tech transfer services, and has developed platforms such as Auto-T for lentiviral vectors and SnapLVV.

In recent news, William S. Marth was appointed President and Chief Executive Officer in December 2024. The company has been strategically streamlining its operations, focusing on high-growth segments like cell-based medicines, biologics, and aseptic drug products. This has involved consolidating its manufacturing footprint and winding down some facilities in California, Massachusetts, and Florida, as its capacity expansion had outpaced industry demand. Resilience has raised over $2 billion in funding since its inception, including an additional $250 million in bridge financing in June 2025, and remains a privately held entity.